Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Breast Milk Pharmacokinetics of Olanzapine and Samidorphan
NCT05547100Phase 1Completed
- Sponsor
- Alkermes
- Start
- Sep 2022
- Primary completion
- Nov 2022
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of olanzapine + samidorphan in schizophrenia and bipolar I disorder, sponsored by Alkermes. Primary endpoints: Area under the concentration-time curve from time zero to 48 hours post-dose, Area under the concentration-time curve from time zero to the time of the last quantifiable concentration up to 15 days and 4 more. Started Sep 2022; status: completed.
02
Drugs
olanzapine + samidorphan
03
Conditions
schizophreniabipolar I disorder
Beyond the preview
Go deeper on NCT05547100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05547100.